Related Experiment Video
Updated: Apr 18, 2026
Biosensor for Detection of Antibiotic Resistant Staphylococcus Bacteria
Published on: May 8, 2013
In vitro and in vivo characterization of a new recombinant antimicrobial peptide, MP1102, against
Yong Zhang1, Da Teng, Xiumin Wang
1Key Laboratory of Feed Biotechnology, Ministry of Agriculture, 100081, Beijing, China.
Abstract:
Currently, more antimicrobial drug candidates are urgently needed to combat the rise in drug-resistance among pathogenic microbes. A new antimicrobial peptide, MP1102, a variant of NZ2114, was designed, evaluated, and overexpressed in Pichia pastoris. The total secreted protein in cultures reached 695 mg/l, and the concentration of the recombinant MP1102 (rMP1102) was 292 mg/l. rMP1102 was purified from the fermentation supernatant by one-step cation exchange chromatography to obtain a yield of 197.1 mg/l with 96.4 % purity. rMP1102 exhibited potent activity against Gram-positive bacteria, and its minimum inhibitory concentrations (MICs) for four Staphyloccocus aureus (S. aureus) strains ranged from 0.028 to 0.11 μM, and it had stronger activity (MIC = 0.04 to 0.23 μM) to 20 clinical isolates of MRSA (cMRSA) than rNZ2114 (MIC = 0.11 to 0.90 μM). rMP1102 was shown to kill over 99.9 % of tested S. aureus cells within 6 h when treated at one, two, and four times its MIC and over 90 % of S. aureus cells within 12 h at concentrations of 5, 10, and 20 mg/kg in a mouse thigh infection model. The higher sensitivity of MRSA to MP1102 than to its parental peptide, NZ2114, indicated by this initial pharmacodynamic analysis suggests a possible difference in the killing mechanism of these two molecules. rMP1102 caused less than 0.05 % hemolytic activity at 128 μg/ml and exhibited good thermostability from 20 to 80 °C, with its highest activity being observed at pH 8.0. These results suggest that this yeast expression system is feasible for large-scale production, and rMP1102 exerted stronger activity against S. aureus than NZ2114 via a different mechanism and exhibited potential as a new antimicrobial agent for S. aureus, especially MRSA infections.
Insights
A novel antimicrobial peptide, MP1102, demonstrates potent activity against Staphylococcus aureus, including methicillin-resistant strains (MRSA). This engineered peptide, produced efficiently in yeast, shows promise as a new therapeutic agent for combating drug-resistant bacterial infections.
Area of Science:
- Microbiology
- Biotechnology
- Pharmacology
Background:
- The rise of antimicrobial resistance necessitates the development of new therapeutic agents.
- Antimicrobial peptides (AMPs) represent a promising class of compounds for combating resistant pathogens.
- MP1102 is a novel variant of the AMP NZ2114, designed to enhance antimicrobial efficacy.
Purpose of the Study:
- To design, evaluate, and optimize the production of the antimicrobial peptide MP1102.
- To assess the antimicrobial activity and potency of MP1102 against Staphylococcus aureus and MRSA.
- To investigate the potential of MP1102 as a therapeutic agent for bacterial infections.
Main Methods:
- MP1102 was designed as a variant of NZ2114 and overexpressed in Pichia pastoris.
- Recombinant MP1102 (rMP1102) was purified using one-step cation exchange chromatography.
- Antimicrobial activity was determined by minimum inhibitory concentrations (MICs) against S. aureus and MRSA strains.
- In vivo efficacy was evaluated using a mouse thigh infection model.
- Hemolytic activity and thermostability were assessed.
Main Results:
- High yields of rMP1102 were achieved (292 mg/l), with purification yielding 197.1 mg/l at 96.4% purity.
- rMP1102 exhibited potent activity against S. aureus (MICs 0.028–0.11 μM) and MRSA (MICs 0.04–0.23 μM), outperforming rNZ2114.
- In vivo studies showed rMP1102 effectively reduced bacterial load in a mouse model.
- rMP1102 demonstrated low hemolytic activity (<0.05%) and good thermostability (20–80 °C).
Conclusions:
- The yeast expression system is suitable for large-scale MP1102 production.
- rMP1102 displays enhanced antimicrobial activity against S. aureus and MRSA compared to its parent peptide.
- MP1102 shows potential as a novel antimicrobial agent, particularly for MRSA infections, possibly through a distinct mechanism of action.
More Related Videos
Related Concept Videos
01:25Clinical Significance of Antibiotic Resistance
01:25Mechanism of Antibiotic Resistance in MRSA